Cargando…

Health Care Utilization Determined From Administrative Claims Analysis for Patients Who Received Inhaled Corticosteroids With Either Montelukast or Salmeterol

Drs. Crownover and Curtiss published separate editorials that made reference to our article on health care utilization among patients with asthma who were treated with inhaled corticosteroids (ICSs) in combination with either montelukast (MON) or salmeterol (SAL). The subject of Crownover's edi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markson, Leona E., Bukstein, Don A., Luskin, Allan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2006
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437321/ https://www.ncbi.nlm.nih.gov/pubmed/16925457 http://dx.doi.org/10.18553/jmcp.2006.12.6.486

Ejemplares similares

Administrative Claims Analysis of Asthma-Related Health Care Utilization for Patients Who Received Inhaled Corticosteroids With Either Montelukast or Salmeterol as Combination Therapy
por: Allen-Ramey, Felicia C., et al.
Publicado: (2006)

Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma
por: Stanford, Richard H, et al.
Publicado: (2012)

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
por: Hodder, Richard, et al.
Publicado: (2007)

Effects on Resource Utilization of Adding Salmeterol in Combination or Separately to Inhaled Corticosteroids
por: Chan, James, et al.
Publicado: (2007)

Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma
por: Scaparrotta, Alessandra, et al.
Publicado: (2012)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
por: Maltais, François, et al.
Publicado: (2019)

Clinical effect of montelukast sodium combined with inhaled corticosteroids in the treatment of OSAS children
por: Yang, Da-Zhi, et al.
Publicado: (2017)

Addition of Montelukast to Low-Dose Inhaled Corticosteroid Leads to Fewer Exacerbations in Older Patients Than Medium-Dose Inhaled Corticosteroid Monotherapy
por: Ye, Young-Min, et al.
Publicado: (2015)

Real-life effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid (ICS) in pediatric patients with uncontrolled asthma
por: Bérubé, Denis, et al.
Publicado: (2014)

Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study
por: Bérubé, Denis, et al.
Publicado: (2014)

Uncovering the regional localization of inhaled salmeterol retention in the lung
por: Bäckström, Erica, et al.
Publicado: (2018)

Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation
por: Sunwoo, Jung, et al.
Publicado: (2017)

Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2
por: Bhattacharyya, Dipankar
Publicado: (2020)

Comparison of vilanterol, a novel long-acting beta(2) agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids
por: Lötvall, Jan, et al.
Publicado: (2014)

Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis
por: Luskin, Allan T, et al.
Publicado: (2016)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
por: Pavord, Ian, et al.
Publicado: (2007)

Inhaled Corticosteroids
por: Barnes, Peter J.
Publicado: (2010)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

Stepping down inhaled corticosteroid use in asthma - who is responsible?
por: Chaudhary, Ashbal, et al.
Publicado: (2015)

Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone
por: Teply, Robyn, et al.
Publicado: (2010)

Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice
por: Singam, Rajeswari, et al.
Publicado: (2006)

Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis
por: Zhou, Xiao-Jian, et al.
Publicado: (2021)

Effectiveness of Montelukast on asthma control in infants: methodology of a French claims data study
por: Belhassen, Manon, et al.
Publicado: (2015)

Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease
por: Riesenfeld, Erik P, et al.
Publicado: (2010)

Replacing nebulizers by MDI-spacers for bronchodilator and inhaled corticosteroid administration: Impact on the utilization of hospital resources
por: Alhaider, S.A., et al.
Publicado: (2014)

Accuracy of the days’ supply and the number of refills allowed recorded in Québec prescription claims databases for inhaled corticosteroids
por: Blais, Lucie, et al.
Publicado: (2014)

A Case of Trigeminal Neuralgia Treated With Combination of Antihistamine, Montelukast, and Corticosteroid Nasal Spray
por: Shahab, Asna, et al.
Publicado: (2020)

Utilization of Inhaled Corticosteroids for Infants with Bronchopulmonary Dysplasia
por: Slaughter, Jonathan L., et al.
Publicado: (2014)

Administrative Claims Analysis of Utilization and Costs of Care in Health Plan Members With Atopic Dermatitis Who Had Prior Use of a Topical Corticosteroid and Who Initiate Therapy With Pimecrolimus or Tacrolimus
por: Delea, Thomas E., et al.
Publicado: (2007)

COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?
por: Maes, Tania, et al.
Publicado: (2020)

The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial
por: Dalby, Chris, et al.
Publicado: (2009)

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects
por: Kirjavainen, Merja, et al.
Publicado: (2018)

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis
por: Yawn, Barbara P, et al.
Publicado: (2013)

Inhaled Corticosteroids and Bone Health
por: Chee, Carolyn, et al.
Publicado: (2014)

Inhaled Corticosteroids and COVID-19
por: Lipworth, Brian, et al.
Publicado: (2020)

Inhaled Corticosteroids and Adult Asthma
por: Boulet, Louis-Philippe, et al.
Publicado: (2019)

Before and beyond Inhaled Corticosteroids
por: Vazquez Guillamet, Rodrigo
Publicado: (2020)

ORAL montelukast versus inhaled beclomethasone in the prophylactic treatment of post ACUTE viral bronchiolitis wheezing
por: Dos Santos, Luciana Zignago Moreira, et al.
Publicado: (2015)

Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies
por: Haughie, Scott, et al.
Publicado: (2020)

Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study
por: Kern, David M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ur4q4oihtvtab91qmsenmo5h8v